Cadila Pharma launches triple-combination therapy for stronger BP control

The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms

Cadila Pharmaceuticals has expanded its cardiovascular portfolio with the launch of Ciledge Trio, a fixed-dose triple-combination therapy aimed at improving blood pressure control and treatment adherence amid India’s rising hypertension burden. 

The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms to deliver sustained BP control, heart rate regulation and long-term cardiovascular protection.

The launch comes as India faces a growing hypertension crisis, with an estimated 220 million adults living with high blood pressure, many of whom remain either undiagnosed or inadequately controlled. Clinical guidelines increasingly recommend combination therapy for patients requiring stronger and sustained BP management.

According to Cadila, the inclusion of cilnidipine offers an added tolerability advantage, with a significantly lower risk of pedal edema compared to conventional calcium channel blockers. Combined with telmisartan, the therapy is positioned to support patients with co-existing diabetes and chronic kidney disease, while metoprolol strengthens cardioprotection in those with angina, prior myocardial infarction and heart failure.

Commenting on the launch, Chairman and Managing Director Dr. Rajiv I. Modi said the new therapy is designed to address unmet needs in real-world hypertension management through a guideline-driven approach focused on efficacy, safety and long-term cardiovascular outcomes.

A key differentiator is Cadila’s Tri-tab triple-layer tablet technology, which allows the three active ingredients to be combined in a single high-purity formulation while enhancing stability, minimizing drug-drug incompatibility and supporting consistent plasma levels.

By reducing pill burden through a one-tablet regimen, the company expects better patient adherence and improved long-term outcomes, particularly in high-risk hypertensive patients with underlying cardiac conditions.

With the launch of Ciledge Trio, Cadila continues to deepen its presence in India’s fast-growing cardiology segment while addressing a critical public health need in cardiovascular risk reduction.